OSCR Q3 2025 Earnings Call Summary | Stock Taper
Logo
OSCR

OSCR — Oscar Health, Inc.

NYSE


Q3 2025 Earnings Call Summary

November 7, 2025

Summary of Oscar Health's Q3 2025 Earnings Call

1. Key Financial Results and Metrics

  • Total Revenue: Approximately $3 billion, a 23% increase year-over-year.
  • Membership: Ended the quarter with 2.1 million members, a 28% increase year-over-year.
  • Medical Loss Ratio (MLR): Increased to 88.5%, up 380 basis points year-over-year, primarily due to higher market morbidity.
  • SG&A Expense Ratio: Improved to 17.5%, a reduction of 150 basis points year-over-year.
  • Loss from Operations: $129 million, an increase of $81 million year-over-year.
  • Net Loss: $137 million, an increase of $83 million year-over-year.
  • Adjusted EBITDA Loss: $101 million, a change of $90 million year-over-year.
  • Cash and Investments: Approximately $4.8 billion, including $541 million at the parent level.

2. Strategic Updates and Business Highlights

  • Market Positioning: Oscar is focusing on the individual market, emphasizing its importance for 22 million Americans lacking employer coverage.
  • Product Diversification: Introduction of new products like HelloMeno, targeting women experiencing menopause, and continued success with chronic condition plans.
  • Innovative Offerings: Launch of Oswell, an AI health agent to enhance member experience.
  • Growth Initiatives: Entering new states (Alabama and Mississippi) and expanding existing markets, with a total addressable market for 2026 estimated at $12 million.

3. Forward Guidance and Outlook

  • 2025 Revenue Guidance: Expected to be at the low end of the $12 billion to $12.2 billion range.
  • MLR Guidance: Anticipated to be between 86.0% and 87.0% for the full year.
  • 2026 Pricing Strategy: A weighted average rate increase of approximately 28% is planned, reflecting elevated market morbidity and the expiration of enhanced premium tax credits.
  • Profitability Goals: Oscar aims to return to profitability in 2026, with a disciplined approach to pricing and cost management.

4. Bad News, Challenges, or Points of Concern

  • Increased Market Morbidity: Higher morbidity levels are impacting MLR and overall profitability.
  • Losses: Significant operational and net losses reported, indicating ongoing financial challenges.
  • Membership Churn: Anticipated decline in membership due to historical churn patterns, particularly after the end of the continuous SEP.
  • Regulatory Risks: Potential impacts from program integrity measures and the expiration of enhanced premium tax credits could affect market dynamics and profitability.

5. Notable Q&A Insights

  • Market Morbidity: Analysts inquired about the implications of worsening market morbidity, with management indicating that they expect consistent morbidity levels through year-end.
  • G&A Efficiency: Management expressed confidence in achieving long-term G&A targets despite expected member attrition, citing AI initiatives to streamline costs.
  • Enrollment Trends: Early enrollment activity appears strong, but management is cautious about making projections based on initial data.
  • Competitive Landscape: Oscar is positioned to capture market share as competitors price themselves out, with a focus on maintaining a competitive edge through narrow networks and tailored products.

Overall, Oscar Health is navigating a challenging market environment with a focus on strategic growth, innovative product offerings, and a disciplined approach to pricing and cost management, while also preparing for potential regulatory impacts and market shifts.